权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

A Novel Symbiotic Approach for Ovarian Cancer

治疗卵巢癌的新共生方法

基本信息

批准号：
10621319
负责人：
Jogender Tushir-Singh
金额：
$ 38.08万
依托单位：
UNIVERSITY OF CALIFORNIA AT DAVIS
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-06-01 至 2024-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10621319
关键词：
AKT inhibition Activator Appliances Adaptive Immune System Affect Affinity Agonist Animals Antibodies Antibody Specificity Antibody Therapy Apoptosis Apoptotic Beds Binding Biological Response Modifier Therapy Blood Caliber Cancer Death Rates Cancer Model Cancer Patient Cell Death Cell Death Induction Cells Cessation of life Chemoresistance Clinical Clinical Data Clinical Trials Complex Cytotoxic T-Lymphocytes Data Dimerization Disease Progression Eating Effector Cell Engineering FDA approved FOLR1 gene Female Genital Diseases Folic Acid Antagonists Goals Hematopoietic Neoplasms Home Immune Immune response Immune system Immunocompetent Individual Induction of Apoptosis Infiltration Malignant Neoplasms Malignant neoplasm of ovary Mediating Membrane Membrane Microdomains Modeling Mus Output Pathway interactions Patients Penetration Phagocytes Phagocytosis Platinum Progression-Free Survivals Property Proteins Proto-Oncogene Proteins c-akt Receptor Activation Receptor Signaling Recurrence Regulation Resistance Role Safety Signal Induction Signal Transduction Solid Solid Neoplasm Specificity Surface Surface Antigens T-Cell Depletion TNFRSF10B gene TP53 gene Testing Therapeutic Therapeutic antibodies Tissues antiangiogenesis therapy bevacizumab calreticulin cancer cell cancer immunotherapy caveolin 1 cell type chemotherapy combinatorial cross reactivity cytotoxicity effective therapy efficacious treatment feasibility testing immunogenic cell death immunogenicity improved in vivo individualized medicine loss of function mutation melanoma mouse model neoplastic cell novel ovarian neoplasm patient derived xenograft model receptor recruit resistance mechanism response success therapeutically effective treatment strategy tumor tumor microenvironment

项目摘要

The overall cancer death rates are down ~20% in past 25 years, however they remained unchanged for late stage ovarian cancer (OvCa) patients, making it the deadliest gynecological disease. Cancer immunotherapy makes use of antibody-based approaches to activate immune cells against the cancer cells and have proven effective in blood cancers and melanomas. Despite short-term positive responses, most OvCa specific antibodies have largely failed in clinical trials. This is attributed to limited infiltration of activated immune effector cells into the solid tumor bed. Therefore, it is highly important to generate efficacious therapies that have inbuilt capacity to turn OvCa against itself by exploiting inherent cancer properties. The proposed studies aim to investigate a novel and rationally combined dual-specificity antibody-based approach (called BaCa) that makes use of OvCa enriched surface antigen (FOLR1) and cancer inducible cell-death activator (DR5 or TRAIL-R2). Therapeutic antibodies individually against FOLR1 and DR5 have failed in clinical trials due to lack of efficacy. The BaCa approach combines these two targets in a single agent antibody with combined strength in the activity and selectivity. FOLR1 acts as an anchor to selectivity recruit, retain, and maintain anti-DR5 affinity in the ovarian tumor microenvironment. This results into a high level of DR5 receptor clustering, signaling and activation. As a consequence a highly superior cell death and cytotoxicity is instigated against ovarian tumors. We have already tested the feasibility of BaCa strategy in both ex vivo and in vivo OvCa models. Current application supported with comprehensive preliminary data aims to test the unique ability of BaCa strategy to engage host immune response for long-term immunogenicity against OvCa. If proved accurate and successful in vivo, this path has the inherent “moon-shot” potential to selectively eliminate HGSOC cells, in a similar or improved fashion over FDA approved dual-specificity antibody called blinatumomab. Unlike chemotherapy, proposed biological therapy is safe and will significantly change the landscape of disease progression free survival of OvCa patients. Finally, this strategy has a great potential to be applicable for other solid cancer targeting.

在过去的25年里，总体癌症死亡率下降了约20%，但最近却没有变化

项目成果

期刊论文数量（4）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

A Feasible Alternative Strategy Targeting Furin Disrupts SARS-CoV-2 Infection Cycle.

DOI：
10.1128/spectrum.02364-21
发表时间：
2022-02-23
期刊：
Microbiology spectrum
影响因子：
3.7
作者：
Mondal T;Shivange G;Habieb A;Tushir-Singh J
通讯作者：
Tushir-Singh J

Characterizing the regulatory Fas (CD95) epitope critical for agonist antibody targeting and CAR-T bystander function in ovarian cancer.

DOI：
10.1038/s41418-023-01229-7
发表时间：
2023-11
期刊：
CELL DEATH AND DIFFERENTIATION
影响因子：
12.4
作者：
Mondal, Tanmoy;Gaur, Himanshu;Wamba, Brice E. N.;Michalak, Abby Grace;Stout, Camryn;Watson, Matthew R.;Aleixo, Sophia L.;Singh, Arjun;Condello, Salvatore;Faller, Roland;Leiserowitz, Gary Scott;Bhatnagar, Sanchita;Tushir-Singh, Jogender
通讯作者：
Tushir-Singh, Jogender

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody.

分析靶抗原特异性治疗抗体的肿瘤和组织分布。

DOI：
10.3791/60727
发表时间：
2020
期刊：
Journal of visualized experiments : JoVE
影响因子：
0
作者：
Shivange,Gururaj;Mondal,Tanmoy;Lyerly,Evan;Gatesman,Jeremy;Tushir-Singh,Jogender
通讯作者：
Tushir-Singh,Jogender

Arming "old guards" with "new dual-targeting weapons".

用“新型双目标武器”武装“老卫士”。